Log In


Company Name : Boehringer Ingelheim

Sunday, February 18, 2018 1:59PM IST (8:29AM GMT)


Systemic Sclerosis World Congress: Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease

Ingelheim, Germany

  • 'More Than Scleroderma: The Inside Story' provides real-life stories and education about the life-threatening disease
  • New and truly inspiring patient stories are revealed
  • Help raise awareness of this little-known disease by visiting www.morethanscleroderma.com
  • “I’ve learned how to cope with this disease. There are many important things which I am still capable of doing.”– Anna, 36, living with scleroderma

Boehringer Ingelheim unveils a new phase of 'More Than Scleroderma: The Inside Story', and launches the new patient website www.morethanscleroderma.com.


This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005188/en/

Anna, 36, living with scleroderma (Photo: Business Wire)

Anna, 36, living with scleroderma (Photo: Business Wire)

The global initiative highlights the importance of understanding the ‘inside story’ of each individual living with scleroderma, also known as systemic sclerosis. To coincide with the Systemic Sclerosis World Congress in Bordeaux, 15-17 February 2018, new and truly inspiring patient stories are revealed, reflecting the real-life, diverse and very moving journeys of people living with scleroderma across the world. The campaign will also be launched in the U.S.


The new website www.morethanscleroderma.com features a powerful collection of photographs and video stories of people living with scleroderma across the world, revealing the life-changing impact of the disease.


Anna, from Szombathely in Hungary, has shared her story on the website. She wants to encourage and inspire others with the disease: “I would like to make it clear to others that they are not alone.”


Anna, 36, recalls how “Back when I was originally diagnosed, my world completely fell apart…I found everything terrifying.” She didn’t know anyone else with the disease and couldn’t find positive stories. But Anna learned how to cope with the disease, and after a difficult journey she is happy again and enjoying life. “Today I’m much more grateful for the little things,” she explains.


To see Anna’s story and those of other patients from around the world, visit www.morethanscleroderma.com and https://www.boehringer-ingelheim.com/respiratory/systemic-sclerosis/inside-story


Scleroderma is a rare and potentially fatal disease involving the skin, lungs and other organs.1,2 It typically affects women in the prime of their lives, like Anna, between the ages of 25 and 55.3,4 Most people with the disease will develop some degree of lung scarring, or interstitial lung disease (ILD).1,5,6,7 Currently, there are no approved medicines for treating lung fibrosis associated with scleroderma.


FESCA Seeks Supportive Action


Annelise Rønnow, President of FESCA (The Federation of European Scleroderma Associations) values the opportunity for broad audiences to engage in raising awareness of this rare disease.


“Better awareness of scleroderma and its signs and symptoms should help people get diagnosed earlier, so care and support can be provided,” said Annelise Rønnow. “It is so inspiring and insightful to hear the poignant journeys of people living with the disease. We support ‘More Than Scleroderma: The Inside Story’, for the information and help it can offer people affected by this little-known disease”.


~ ENDS ~


Please click on the link below for ‘Notes to Editors’ and ‘References’:




Intended audiences:


This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.





Click here for Media Contact Details

Boehringer Ingelheim
Corporate Communications
Media + PR
Dr. Kristin Jakobs
Phone: +49 6132 – 77 144553
Fax: +49 6132 – 77 6601
Email: press@boehringeringelheim.com

More News from Boehringer Ingelheim

20/03/2018 5:45PM

Favorable safety profile of Pradaxa® (dabigatran etexilate) confirmed in large prospective real-world analysis

Complete Phase II results from the prospective GLORIATM-AF registry in dabigatran patients presented as a late-breaker at the EHRA 2018, the annual congress of the European Heart Rhythm Association (EHRA)1 Low ...

19/03/2018 7:15PM

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease ...

07/03/2018 10:59AM

Boehringer Ingelheim and Lilly expand heart failure programme for empagliflozin with new exercise capacity trials

EMPERIAL clinical trials will evaluate the effect of empagliflozin on exercise ability and heart failure symptoms in people with chronic heart failure1,2 EMPERIAL is part of the most comprehensive clinical trial ...

Similar News

23/03/2018 7:12PM

Corporate Social Responsibility Related News Releases and Story Ideas for Reporters, Bloggers and Media Outlets

Following are the latest Corporate Social Responsibility news releases and story ideas available from Business Wire. These recaps, curated by Business Wire, provide reporters and bloggers around the globe instant access ...

No Image

23/03/2018 5:47PM

बीआइआरएसी और पर्किनएल्‍मर ने भारत प्रवर्तित स्‍टार्टअप्‍स और नवाचारों को बढ़ावा देने के लिए आशय पत्र पर हस्‍ताक्षर किये

बायोटेक्‍नोलॉजी इंडस्‍ट्री रिसर्च असिस्‍टेंस काउंसिल (बीआइआरएसी) ने मंगलवार को नई दिल्‍ली में अपना छठा स्‍थापना दिवस मनाया। इस कार्यक्रम का मुख्‍य विषय था “नवाचारको बरकरार रखना: ...